ArticleFrontiers in pharmacology2026
Efficacy and safety of adjuvant low-dose apatinib combined with SOX regimen versus SOX regimen in patients with resectable locally advanced gastric cancer: a cohort study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical efficacy and safety of apatinib plus S-1 combined with oxaliplatin (SOX) in postoperative stage III gastric cancer patients with high VEGFR-2 expression.Journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Apatinib combined with S-1 and oxaliplatin (SOX) synergistically improves the prognosis of advanced gastric cancer patients, but its application as an adjuvant regimen has rarely been reported. This study aimed to investigate the efficacy and safety of adjuvant low-dose apatinib combined with SOX versus SOX alone in patients with resectable locally advanced gastric cancer. Methods: This cohort study included 110 patients with locally advanced gastric cancer (pTNM stage III) who underwent radical surgery. Among these patients, 70 patients received adjuvant low-dose apatinib (250 mg/day) combined with SOX regimen (named apatinib + SOX group), and 40 patients received adjuvant SOX regimen alone (named SOX group). Disease-free survival (DFS) and adverse events were recorded. Results: DFS was longer in apatinib + SOX group versus SOX group ( Conclusion: Low-dose apatinib combined with SOX may be a feasible adjuvant regimen in patients with resectable locally advanced gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.